-+ 0.00%
-+ 0.00%
-+ 0.00%

INNOVENT ANNOUNCES IBI363 (PD-1/IL-2Α-BIAS BISPECIFIC FUSION PROTEIN) RECEIVED THIRD NMPA BREAKTHROUGH THERAPY DESIGNATION FOR MSS/PMMR METASTATIC COLORECTAL CANCER

Reuters·05/11/2026 00:00:07

Please log in to view news